Evaluating the Newly Proposed ARDS Definition in Hospitalized Patients With COVID-19 Treated With High-Flow Nasal Oxygen.

Publication date: Oct 29, 2024

The new Global definition of ARDS recently introduced a subgroup known as non-intubated ARDS. This study aimed to assess the risk of progression from noninvasive oxygen support to intubation and ARDS severity based on the S /F among non-intubated subjects with ARDS. This retrospective study included subjects with COVID-19 admitted to 7 hospitals (5 in the United States and 2 in Argentina) from January 2020-January 2023. Subjects meeting the new non-intubated ARDS definition (high-flow nasal cannula [HFNC] with an S /F ≤ 315 [with S ≤ 97%] or a P /F ≤ 300 mm Hg while receiving ≥30 L/min O via HFNC) were included. The study evaluated the proportion of subjects who progressed to intubation, severity levels using the S /F cutoff proposed in the new ARDS definition, and mortality. Nine hundred sixty-five non-intubated subjects with ARDS were included, of whom 27% (n = 262) progressed to meet the Berlin criteria within a median of 3 d (interquartile range 2-6). The overall mortality was 23% (95% CI 20-26) (n = 225), and among subjects who progressed to the Berlin criteria, it was 37% (95% CI 31-43) (n = 98). Additionally, the worst S /F within 1 d of ARDS diagnosis was correlated with mortality, with mortality rates of 26% (95% CI 23-30) (n = 177) for subjects with S /F ≤ 148, 17% (95% CI 12-23) (n = 38) for those with S /F between 149-234, and 16% (95% CI 8-28) (n = 10) for subjects maintaining an S /F higher than 235 (P < .001). The non-intubated ARDS criteria encompassed a broader spectrum of subjects with lower in-hospital mortality compared to the Berlin criteria. The S /F and ARDS severity cutoff proposed in the new Global ARDS definition were valuable predictors of in-hospital mortality in these subjects.

Open Access PDF

Concepts Keywords
Argentina ARDS
Berlin coronavirus disease 2019
Hospitals critical care
Valuable oxygen saturation

Semantics

Type Source Name
disease MESH COVID-19
drug DRUGBANK Oxygen
drug DRUGBANK Clofazimine
drug DRUGBANK Coenzyme M
disease MESH tuberculosis
pathway KEGG Tuberculosis
drug DRUGBANK Methyl isocyanate
drug DRUGBANK Bedaquiline
drug DRUGBANK Linezolid
drug DRUGBANK Delamanid
drug DRUGBANK Pretomanid
disease MESH infection
disease IDO bactericidal
disease IDO drug susceptibility
disease IDO susceptibility
disease MESH deletion mutations
disease MESH point mutations
disease IDO immunodeficiency
disease MESH lung disease
disease MESH immunosuppressed hosts
drug DRUGBANK Nonoxynol-9

Original Article

(Visited 2 times, 1 visits today)